U.S. BIOSCIENCE GRANTS SCHERING-PLOUGH MARKETING RIGHTS TO PRODUCTS IN LATIN AMERICA AND FAR EAST
U.S. BIOSCIENCE GRANTS SCHERING-PLOUGH MARKETING RIGHTS
TO PRODUCTS IN LATIN AMERICA AND FAR EAST
WEST CONSHOHOCKEN, Pa., Nov. 19 /PRNewswire/ -- U.S. Bioscience Inc. (AMEX: UBS), a pharmaceutical company specializing in the development and commercialization of anti-cancer compounds, today announced that it has signed an agreement in principle with Schering- Plough Corp. directed toward granting it marketing rights to Hexalen(R), Ethyol(R), WR-151327, PALA and Rogletimide for a number of countries in Latin America and the Far East.
Hexalen has been approved by the U.S. Food and Drug Administration and is used in the treatment of ovarian cancer. Ethyol, for which a New Drug Application has been filed with the FDA, is a radiation- and chemotherapy-protective agent. PALA, a drug in the final stages of development, is aimed at enhancing the activity of certain chemotherapeutic agents. Rogletimide is a drug for the treatment of breast cancer.
"In Schering-Plough, we have chosen a company that historically has had strong marketing, sales and product registration capabilities in the oncology market, which will help to optimize the potential of these products in these regions," said Philip S. Schein, M.D., chairman and chief executive officer. "We are pleased to be affiliated with this type of organization. The completion of this agreement will represent an important step to the company as we attempt to expand our efforts internationally in markets where U.S. Bioscience may have a limited chance of succeeding on its own."
Known for the quality of its products and the integrity of its people, Schering-Plough, based in Madison, N.J., is a research-based company involved in the research, development, manufacturing and marketing of pharmaceutical and healthcare products worldwide.
Based in West Conshohocken, U.S. Bioscience is a pharmaceutical company specializing in the development and commercialization of products to increase the survival and quality of life for patients with cancer and allied diseases.
/CONTACT: Robert I. Kriebel of U.S. Bioscience, 215-832-4503; or Charles Versaggi of Versaggi & Associates for U.S. Bioscience, 408-358-4162 or 408-395-1877/
(UBS) CO: U.S. Bioscience ST: Pennsylvania IN: MTC SU: JL -- SJ003 -- 4772 11/19/91 08:03 EST